{
    "title": "Teva Pharm bets on neurology drugs for growth as Q1 profit misses",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12068037/Teva-Pharm-Q1-net-profit-slides-maintains-2023-forecast.html",
    "date": "2023-05-10",
    "keywords": [
        "francis",
        "teva",
        "revenue",
        "year",
        "company",
        "share",
        "scheer",
        "growth",
        "profit",
        "product",
        "ajovy",
        "drug",
        "pipeline",
        "business",
        "tevas",
        "jerusalem",
        "drugmaker",
        "trio",
        "miss",
        "ceo",
        "richard",
        "start",
        "treatment",
        "uzedy",
        "recover",
        "attention",
        "part",
        "capability",
        "cash",
        "debt",
        "exclusivity",
        "blockbuster",
        "sclerosis",
        "copaxone",
        "drop",
        "spate",
        "time",
        "traction",
        "risperidone",
        "market",
        "january",
        "period",
        "refinitiv",
        "result",
        "morning",
        "york",
        "trading",
        "inflation",
        "versus",
        "austedo",
        "strategy",
        "week",
        "stage",
        "neuroscience",
        "lot",
        "area",
        "loss",
        "reporting",
        "editing",
        "louise",
        "donovan",
        "jan",
        "harvey"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}